Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Bile Acids in Patients With Peroxisomal Disorders
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2000 by FDA Office of Orphan Products Development.
Recruitment status was  Not yet recruiting
Study NCT00004442   Information provided by FDA Office of Orphan Products Development

First Received on October 18, 1999.   Last Updated on June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Infantile Refsum's Disease
Zellweger Syndrome
Bifunctional Enzyme Deficiency
Adrenoleukodystrophy
Additional conditions recognized in this trial
Peroxisomal Disorders
Refsum Disease
Refsum Disease, Infantile
More general conditions related to this trial
Abnormalities, Multiple
Adrenal Gland Diseases
Adrenal Insufficiency
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Congenital Abnormalities
Demyelinating Diseases
Digestive System Diseases
Endocrine System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Hereditary Central Nervous System Demyelinating Diseases
Hereditary Sensory and Motor Neuropathy
Heredodegenerative Disorders, Nervous System
Kidney Diseases
Leukoencephalopathies
Liver Diseases
Mental Retardation
Mental Retardation, X-Linked
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Nervous System Malformations
Neurobehavioral Manifestations
Neurodegenerative Diseases
Neurologic Manifestations
Neuromuscular Diseases
Peripheral Nervous System Diseases
Polyneuropathies
Urologic Diseases
Interventions listed in this trial
chenodeoxycholic acid
cholic acid
ursodiol
Additional drug interventions recognized in this trial
Cholic Acids
Ursodeoxycholic Acid
More general drug interventions related to this trial
Cathartics
Cholagogues and Choleretics
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
FDA Office of Orphan Products Development
Children's Hospital Medical Center, Cincinnati


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services